Research programme: muscular dystrophy gene therapy - Tapestry Pharmaceuticals
Alternative Names: DMD gene therapy - NaPro BioTherapeutics; Muscular dystrophy gene therapy - NaPro BioTherapeuticsLatest Information Update: 10 Aug 2005
At a glance
- Originator Tapestry Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Genetic transcription inhibitors; Genetic transcription stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular dystrophies
Most Recent Events
- 10 Aug 2005 Discontinued - Preclinical for Muscular dystrophy in USA (unspecified route)
- 11 May 2004 Napro Biotherapeutics is now called Tapestry Pharmaceuticals
- 11 Dec 2003 Preclinical trials in Muscular dystrophy in USA (unspecified route)